YJA 203791

Drug Profile

YJA 203791

Latest Information Update: 02 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yung-Jin Pharmaceutical
  • Class Antiulcers
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Peptic ulcer

Most Recent Events

  • 02 Dec 2003 No development reported - Preclinical for Peptic ulcer in South Korea (PO)
  • 18 Sep 2000 A preclinical study has been added to the adverse events section
  • 31 Mar 2000 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top